Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Completed
Conditions studied: Ovarian Cancer
In brief
This multicenter, observational, prospective study will include approximately 20 US-based centers, and approximately 142 patients diagnosed with epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma, whose disease has recurred \> 6 months after first-line platinum-based chemotherapy (first recurrence). Patients who have completed second-line chemotherapy and are currently in observation or undergoing bevacizumab maintenance treatment will be eligible to participate in the study.
Key facts
- Study ID
- NCT01422265
- Run by
- Genentech, Inc.
- People needed
- 56
- Starts
- 2011-06-01
- Expected to finish
- 2015-04-01
- Last updated by the study team
- 2016-11-02
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Histologically documented ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma that has recurred > 6 months after platinum-based chemotherapy
- This must be the first recurrence of the epithelial ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma
- Are at least two weeks but no more than 3 months after the completion of second-line cytotoxic chemotherapy
- Are currently under observation or being treated with bevacizumab as a second-line maintenance therapy
- Have a valid email address and access to the internet
- Provide voluntary written informed consent
- Speak and read English fluently
You may not qualify if…
- Current participation in a blinded clinical trial for ovarian cancer treatment. (Participation in a trial involving only supportive care medicines and/or growth factors is acceptable)
- Another primary diagnosis of cancer in a different site
Where it is running
- Study site — Goodyear, Arizona, United States
- Study site — Phoenix, Arizona, United States
- Study site — Tucson, Arizona, United States
- Study site — Salinas, California, United States
- Study site — Whittier, California, United States
- Study site — Englewood, Colorado, United States
- Study site — Farmington, Connecticut, United States
- Study site — New Britain, Connecticut, United States
- Study site — Augusta, Georgia, United States
- Study site — Hinsdale, Illinois, United States
- Study site — Joliet, Illinois, United States
- Study site — Skokie, Illinois, United States
- Study site — Indianapolis, Indiana, United States
- Study site — Indianapolis, Indiana, United States
- Study site — Baltimore, Maryland, United States
- Study site — Cumberland, Maryland, United States
- Study site — Missoula, Montana, United States
- Study site — Lincoln, Nebraska, United States
- Study site — Buffalo, New York, United States
- Study site — New York, New York, United States
- Study site — Watertown, New York, United States
- Study site — Canton, Ohio, United States
- Study site — Cleveland, Ohio, United States
- Study site — Columbus, Ohio, United States
- Study site — Oklahoma City, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.